Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexagliflozin PK Interaction with Metformin, Glimepiride, or Sitagliptin
NCT02956044Phase 1Completed
- Sponsor
- Theracos, Inc.
- Start
- Nov 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bexagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Theracos, Inc. Primary endpoints: Maximum Observed Plasma Concentration up to 72 hours, Time of Maximum Observed Plasma Concentration up to 72 hours and 2 more. Started Nov 2016; status: completed.
02
Drugs
bexagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02956044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02956044.